The Added Benefit of Intra-Arterial Thrombolysis After Successful Recanalization by Endovascular Treatment: A...

Despite successful recanalization following endovascular thrombectomy (EVT) for acute ischemic stroke (AIS) with large-vessel occlusion (LVO), many patients fail to achieve excellent functional outcomes. Post-EVT intra-arterial thrombolysis (IAT) has emerged as a potential adjunctive strategy to improve microvascular reperfusion and clinical recovery.

We conducted a systematic review and meta-analysis of randomized-controlled clinical trials (RCTs) comparing IAT plus best medical therapy (BMT) versus BMT alone in LVO-AIS patients with successful recanalization post-EVT. The primary efficacy outcome was 3-month excellent functional outcome [modified Rankin Scale (mRS)-score: 0-1]. Secondary efficacy outcomes included good functional outcome (mRS-score: 0-2) and reduced disability (mRS-score shift analysis) at 3 months. The primary safety outcome was symptomatic intracranial hemorrhage (sICH); secondary safety outcomes included any-ICH and 3-month all-cause mortality. Subgroup and network meta-analyses were performed evaluating the effects of different thrombolytic agents.

Seven RCTs were included, comprising 1083 patients treated with IAT and 1048 patients treated with BMT alone. IAT was associated with higher likelihood of excellent functional outcome (RR: 1.23; 95% CI: 1.11-1.36; I² = 0%) and reduced disability at 3 months (common-OR: 1.10; 95% CI: 1.03-1.18; I² = 0%) compared with BMT alone. Similar rates of 3-month good functional outcome, 3-month mortality, sICH and any-ICH were observed. Although no significant subgroup differences emerged, in the network meta-analysis alteplase ranked highest in efficacy [surface under the cumulative rank curve (SUCRA): 90%], followed by tenecteplase (61%) and urokinase (40%) in achieving 3-month excellent functional outcome.

IAT improves excellent functional outcomes without compromising safety in LVO-AIS patients with successful recanalization after EVT.

The prespecified protocol of the present systematic review and meta-analysis has been registered in the International Prospective Register of Ongoing Systematic Reviews PROSPERO (registration ID: CRD420251035903).